Marshall Wace LLP Takes Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Marshall Wace LLP purchased a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,097,762 shares of the company's stock, valued at approximately $13,909,000. Marshall Wace LLP owned 1.09% of Day One Biopharmaceuticals as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. lifted its stake in shares of Day One Biopharmaceuticals by 11.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 21,383 shares of the company's stock valued at $271,000 after buying an additional 2,180 shares during the period. R Squared Ltd acquired a new position in Day One Biopharmaceuticals in the 4th quarter valued at $31,000. Swiss National Bank lifted its stake in shares of Day One Biopharmaceuticals by 2.6% during the 4th quarter. Swiss National Bank now owns 117,800 shares of the company's stock worth $1,493,000 after purchasing an additional 3,000 shares during the period. Teacher Retirement System of Texas lifted its stake in shares of Day One Biopharmaceuticals by 20.9% during the 4th quarter. Teacher Retirement System of Texas now owns 17,825 shares of the company's stock worth $226,000 after purchasing an additional 3,086 shares during the period. Finally, Handelsbanken Fonder AB boosted its holdings in shares of Day One Biopharmaceuticals by 16.7% during the fourth quarter. Handelsbanken Fonder AB now owns 31,500 shares of the company's stock worth $399,000 after purchasing an additional 4,500 shares during the last quarter. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 4,646 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $55,566.16. Following the transaction, the general counsel now directly owns 39,602 shares of the company's stock, valued at $473,639.92. This represents a 10.50 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Charles N. York II sold 4,370 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $52,265.20. Following the transaction, the chief financial officer now owns 252,638 shares in the company, valued at $3,021,550.48. This represents a 1.70 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 21,064 shares of company stock valued at $251,925 over the last three months. Insiders own 8.40% of the company's stock.

Day One Biopharmaceuticals Stock Down 2.0 %

DAWN stock traded down $0.16 during trading on Friday, reaching $7.74. 728,454 shares of the company's stock were exchanged, compared to its average volume of 1,170,935. Day One Biopharmaceuticals, Inc. has a 1-year low of $6.41 and a 1-year high of $18.07. The firm has a market cap of $784.48 million, a PE ratio of -7.51 and a beta of -1.24. The company's fifty day moving average price is $8.44 and its 200-day moving average price is $11.64.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The firm had revenue of $29.21 million during the quarter, compared to analyst estimates of $27.11 million. As a group, sell-side analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Bank of America reduced their target price on Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating on the stock in a research report on Tuesday, January 7th. Needham & Company LLC reissued a "buy" rating and issued a $32.00 target price on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Wedbush restated an "outperform" rating and issued a $32.00 target price on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. JPMorgan Chase & Co. cut their price target on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating on the stock in a research note on Wednesday, March 5th. Finally, The Goldman Sachs Group lowered their price objective on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating for the company in a research note on Tuesday, March 25th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $32.29.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.